Lymphoma risk in systemic lupus: effects of disease activity versus treatment.

نویسندگان

  • Sasha Bernatsky
  • Rosalind Ramsey-Goldman
  • Lawrence Joseph
  • Jean-Francois Boivin
  • Karen H Costenbader
  • Murray B Urowitz
  • Dafna D Gladman
  • Paul R Fortin
  • Ola Nived
  • Michelle A Petri
  • Soren Jacobsen
  • Susan Manzi
  • Ellen M Ginzler
  • David Isenberg
  • Anisur Rahman
  • Caroline Gordon
  • Guillermo Ruiz-Irastorza
  • Edward Yelin
  • Sang-Cheol Bae
  • Daniel J Wallace
  • Christine A Peschken
  • Mary Anne Dooley
  • Steven M Edworthy
  • Cynthia Aranow
  • Diane L Kamen
  • Juanita Romero-Diaz
  • Anca Askanase
  • Torsten Witte
  • Susan G Barr
  • Lindsey A Criswell
  • Gunnar K Sturfelt
  • Irene Blanco
  • Candace H Feldman
  • Lene Dreyer
  • Neha M Patel
  • Yvan St Pierre
  • Ann E Clarke
چکیده

OBJECTIVE To examine disease activity versus treatment as lymphoma risk factors in systemic lupus erythematosus (SLE). METHODS We performed case-cohort analyses within a multisite SLE cohort. Cancers were ascertained by regional registry linkages. Adjusted HRs for lymphoma were generated in regression models, for time-dependent exposures to immunomodulators (cyclophosphamide, azathioprine, methotrexate, mycophenolate, antimalarial drugs, glucocorticoids) demographics, calendar year, Sjogren's syndrome, SLE duration and disease activity. We used adjusted mean SLE Disease Activity Index scores (SLEDAI-2K) over time, and drugs were treated both categorically (ever/never) and as estimated cumulative doses. RESULTS We studied 75 patients with lymphoma (72 non-Hodgkin, three Hodgkin) and 4961 cancer-free controls. Most lymphomas were of B-cell origin. As is seen in the general population, lymphoma risk in SLE was higher in male than female patients and increased with age. Lymphomas occurred a mean of 12.4 years (median 10.9) after SLE diagnosis. Unadjusted and adjusted analyses failed to show a clear association of disease activity with lymphoma risk. There was a suggestion of greater exposure to cyclophosphamide and to higher cumulative steroids in lymphoma cases than the cancer-free controls. CONCLUSIONS In this large SLE sample, there was a suggestion of higher lymphoma risk with exposure to cyclophosphamide and high cumulative steroids. Disease activity itself was not clearly associated with lymphoma risk. Further work will focus on genetic profiles that might interact with medication exposure to influence lymphoma risk in SLE.

برای دانلود رایگان متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

ثبت نام

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

منابع مشابه

Maternal, Fetal and Neonatal Outcomes in Pregnant Women with Systemic Lupus Erythematosus: A Comprehensive Review Study

Background:Systemic lupus erythematosus (SLE) is an autoimmune disease with multiple organ involvement and periods of relapse and remission that mainly affects young women of childbearing age. In this regard the reproductive health is an important issue. Although diagnosis, treatment and management of pregnancy in SLE women have been improved recently, but the main concern is effects of SLE on ...

متن کامل

IL-17 is Aberrantly Overexpressed Among Under-treatment Systemic Lupus Erythematosus Patients

Background & Objective: Systemic lupus erythematosus (SLE) is an autoimmune disease with chronic inflammatory immune response. Current therapies mostly rely on glucocorticoids which are accompanied by side-effects and mostly fail to achieve a favorable remission. Th17 subpopulation of T cells is increased in exacerbated SLE as IL-17 cytokine is overexpressed. ...

متن کامل

Codon 72 Polymorphism of p53 Gene and Hematologic Manifestations in Patients with Systemic Lupus Erythematosus

Background: Systemic lupus erythematosus is a systemic autoimmune disorder with unclear etiology. The importance of some genes in the development of systemic lupus erythematosus has been implicated. The gene polymorphism in codon 72 has attracted a lot of attention and its role in the occurrence or progression of many cancers and autoimmune diseases especially systemic lupus erythematosus has ...

متن کامل

Ratio of Th17/Treg and Disease Activity in Systemic Lupus Erythematosus

Background: Systemic lupus erythematosus (SLE) is an autoimmune disease that is characterized by T-cells imbalance. There are ongoing controversies about the role of specific T-helper cell subsets and their cytokines. The study aimed to confirm the disturbance of Th17/Treg ratio in SLE patients. Methods: Subjects were SLE patients who met the American College of Rheumatology 1997 criteria. Dis...

متن کامل

نتایج درمان نفریت لوپوسی پرولیفراتیو مقاوم به درمان با سیکلوسپورین A

Background & Aims: Systemic lupus erythematosus (SLE) is a chronic autoimmune disease characterized by various autoantibodies formation and immune complex deposition in various organs. Lupus nephritis is a common and severe manifestation of SLE that can lead to end stage renal disease and death. The aim of this study was to evaluate the long-term efficacy of cyclosporine A in the treat...

متن کامل

ذخیره در منابع من


  با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید

عنوان ژورنال:
  • Annals of the rheumatic diseases

دوره 73 1  شماره 

صفحات  -

تاریخ انتشار 2014